MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'allos'. Sat, 03 Sep 2011 02:58:53 +0100 http://www.medworm.com/index.php?rid=4349700&cid=t_131144_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F5NrfDeio_0c%2F And so another working week will soon draw to a close. In this case, a long weekend is about to begin, at least on this side of the pond. Have any special plans? We expect to tidy up around the Pharmalot corporate campus, spend time with our short and not-so-short people, and take a long walk or two. What about you? Take in a movie or read a good book? Maybe get rid of some flab? Whatever you do, have a great time and come back energized. Meanwhile, here are a few tidbits to help you along. See you next week… Abbott Labs Withdraws Psoriasis Drug (Wall Street Journal) Sanofi Tells Docs About Liver Transplants In Multaq Patients (CardioBrief) Glaxo Malaria Vaccine Works For 15 Months: Study (Bloomberg News) Ambien Makes Older People Too Sleepy (Reuters) Allos Therapeutics Lays Off 13 P... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4349700 Fri, 14 Jan 2011 13:00:43 +0100 4349700 http://www.medworm.com/index.php?rid=3075458&cid=t_131144_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2009%2F12%2Fmore-air-into-health-care-bubble-30000.html Over four years ago, we posted about the stratospheric prices of new drugs that seemed disproportionate to manufacturing and development costs on one hand, and the value of the drugs for patients on the other.  For example, back then we noted that thalidomide, a very old drug that notoriously was found to cause birth defects when it was given to preganant women, but that then showed promise as an anti-cancer drug, was being marketed in the US for $29 per capsule (approximately $25,000 a year), while a generic form sold in Brazil for $0.07 per capsule.That was then, and this is now.  This week, the New York Times reported on a $30,000+  per month cancer drug.  A newly approved chemotherapy drug will cost about $30,000 a month, a sign that the prices of cancer m... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=3075458 Wed, 09 Dec 2009 21:56:00 +0100 3075458 http://www.medworm.com/index.php?rid=3067313&cid=t_131144_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FnCqCy9SeLUc%2F The price for Folotyn, which was was approved to treat relapsed or refractory peripheral T-cell lymphoma, a rare blood cancer that hits about 5,600 people in the US each year, seems certain to cause controversy as health care reform legislation is debated. As The New York Times notes, the drug shrink tumors, but has not been shown to prolong lives. Allos defends the price, saying it made a significant investment to develop the first approved drug for this type of cancer. “It’s a very aggressive disease, and patients right now have no options,” Jim Caruso, chief commercial officer for Allos Therapeutics, which expects to begin selling the drug next month, tells the paper. “We believe we are fairly priced and we’re benchmarked” against other drugs. However, the paper points o... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3067313 Mon, 07 Dec 2009 17:57:54 +0100 3067313 http://www.medworm.com/index.php?rid=728696&cid=t_131144_150_f&fid=35781&url=http%3A%2F%2Fwww.qdinformation.com%2Fqdisblog%2F2007%2F07%2F09%2Fallos-brain-cancer-drug-fails-phase-3-trials%2F Allos had a disappointing failure in phase III for efaproxyn for treatment of brain cancer that originated from breast cancer. Allos’ Brain Cancer Drug Flops in Phase 3 - Health - RedOrbit: In typical upbeat company fashion, they said they were disappointed but immediately started proclaiming their pipeline and how promising it is. This seems to be very common these days. I know there is the need to proclaim \the positive and negate the negatives but it seems to be out of balance in many of these sorts of press releases. Technorati Tags: Allos Copyright © 2007 QDIS Blog. This Feed is for personal non-commercial use only. If you are not reading this material in your news aggregator, the site you are looking at is guilty of copyright infringement. Please contact legal@qdinformati... QDIS Blog blogs http://www.medworm.com/rss/comments.php?id=728696 Mon, 09 Jul 2007 17:37:35 +0100 728696